CorMedix stock price target raised to $17 from $13 at RBC Capital

RBC Capital raised its price target on CorMedix (CRMD) to $17 from $13, maintaining an Outperform rating, citing expected strength in the outpatient segment and potential from the DefenCath franchise. This follows CorMedix's Q1 2025 earnings beat, with EPS at $0.32 versus the $0.16 forecast and revenue exceeding expectations by over $6 million at $39.1 million; the company anticipates continued growth driven by new product launches and partnerships, targeting FDA approval for a new indication by late 2027.

Analysis

RBC Capital has raised its price target for CorMedix to $17.00 from $13.00, maintaining an Outperform rating, driven by anticipated continued strength in the DefenCath franchise, particularly within the outpatient segment during the second half of 2025. The firm projects robust performance stemming from growth in the existing MDO ordering base, LDO uptake, and an acceleration in the inpatient sector, believing volume growth will substantially mitigate potential revenue declines post-TDAPA, and views CorMedix as a profitable biotech with growth momentum and no tariff or IP risks. A significant contributor to this outlook is the total parenteral nutrition (TPN) opportunity, estimated to potentially add up to $150 million in peak revenues, with further upside identified from CMS negotiations, Medicare Advantage pricing, and expansion into new indications like oncology. This optimistic analyst assessment follows CorMedix's strong first-quarter 2025 results, where earnings per share reached $0.32, doubling the $0.16 forecast, and revenue hit $39.1 million, exceeding expectations by over $6 million. This performance, attributed to successful product launches including DefendCath and strategic partnerships, led to a net income of $20.6 million, a notable turnaround from a net loss in the prior year's corresponding quarter. CorMedix has subsequently revised its first-half 2025 net revenue guidance upwards to approximately $70 million and is targeting a mid-year implementation start with a large dialysis operator, alongside aiming for FDA approval for a new indication by late 2027. The company reported $77.5 million in cash and cash equivalents as of March 31, 2025, and despite a significant 206% stock return over the past year, it acknowledges potential risks including increased R&D expenses and reliance on specific revenue streams, which it aims to manage through market expansion and reimbursement strategies.

Key Decisions for Investors

• Investors may find CorMedix's current trajectory compelling, supported by the upgraded analyst price target, strong Q1 2025 earnings, positive revenue guidance for H1 2025, and a reported 206% stock return over the past year.
• Key milestones to monitor include the continued adoption of DefenCath, the progress of the large dialysis operator partnership, successful FDA approval for new indications by late 2027, and outcomes of CMS negotiations, as these are significant potential value drivers.
• While the outlook is bullish, careful attention should be paid to the company's management of R&D expenses and its strategies to mitigate risks associated with revenue concentration from specific sources.